ICON plc (NASDAQ: ICLR), a global provider
of drug development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
all resolutions at the Annual General Meeting of the Company (AGM)
held on July 25, 2017 (which resolutions had all been recommended
by the Board) were all duly passed by shareholders. These
resolutions were set out in the Notice of the AGM sent to
shareholders dated June 23, 2017 and are available on the
ICON plc website.
The final results of the voting are as follows:
RESOLUTION NUMBER RESOLUTION TOTAL
NUMBER OF VOTES VOTE FOR VOTE
AGAINST VOTE WITHHELD 1.1 To
re-elect Prof. Dermot Kelleher 45,317,741 44,238,348 1,032,397
46,996
1.2 To re-elect Prof. Hugh Brady 45,317,741
44,918,234 352,536 46,971
1.3 To re-elect Ms. Mary
Pendergast 45,317,741 44,917,849 351,464 48,428
1.4 To
re-elect Mr. Ronan Murphy 45,317,741 44,630,167 640,062 47,512
2 To receive accounts and reports 45,317,741 45,142,850
3,142 171,749
3 To authorise the fixing of the auditors’
remuneration 45,317,741 41,762,920 3,548,967 5,854
4 To
authorise the Company to allot shares 45,317,741 44,310,484 865,120
142,137
5** To disapply pre-emption rights 45,317,741
44,917,093 238,190 162,458
6** To disapply pre-emption
rights for funding capital investment or acquisitions 45,317,741
44,918,013 237,460 162,268
7** To authorise the Company to
make market purchases of shares 45,317,741 45,177,034 9,283 131,424
8** To authorise the price range at which the Company can
reissue shares it holds as treasury shares 45,317,741 44,962,079
121,491 234,171
** Special Resolution. All resolutions are ordinary resolutions
unless otherwise stated.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 84 locations in 38 countries and has approximately
12,300 employees. Further information is available at
www.iconplc.com.
Source: ICON plc
ICON/ICLR-F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170726005085/en/
ICON plcInvestor Relations1-888-381-7923orBrendan
BrennanChief Financial Officer+ 353 –1-291-2000orJonathan
CurtainVice President Corporate Finance and Investor Relations+1
215 616 3000
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024